Nicotine inhalation - Aradigm Corporation

Drug Profile

Nicotine inhalation - Aradigm Corporation

Alternative Names: ARD-1600

Latest Information Update: 23 Dec 2015

Price : $50

At a glance

  • Originator Aradigm Corporation
  • Class Alkaloids; Analgesics; Drug withdrawal therapies; Nicotine replacement therapy; Pyridines; Small molecules
  • Mechanism of Action Nicotinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Smoking withdrawal

Most Recent Events

  • 23 Dec 2015 Phase-I development is ongoing in USA; programme is still available for licensing
  • 10 Sep 2012 Phase-I development is ongoing in USA
  • 14 Jul 2010 ARD 1600 is available for licensing in USA (http://www.aradigm.com/products_1600.html)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top